FDA-approved arthritis drug may work in new ways to fight itch
The roots of chronic itching have long remained a mystery. Meanwhile, those with the condition suffer from an unrelenting and sometimes debilitating urge to scratch. Now, new research at Washington University School of Medicine in St. Louis has identified immune signaling molecules that are essential for activating neurons in the skin to cause chronic itching.
In a small study, the researchers also discovered that people with a type of itch from an unknown cause, a condition called chronic idiopathic pruritus, improve when given tofacitinib (Xeljanz), a drug approved for rheumatoid arthritis. Earlier attempts to treat their itching with other anti-inflammatory drugs had not been successful, but within one month of taking tofacitinib, all five patients in the study experienced marked relief from severe itching.
The findings are published Sept. 8 in the journal Cell.
“These patients often itch day and night, and for some of them, the urge to scratch never goes away,” said senior investigator Brian S. Kim, MD, an assistant professor of medicine and co-director of Washington University’s Center for the Study of Itch. “Although this was a small study, the patients taking tofacitinib experienced dramatic improvements in terms of their itch, allowing them to sleep, stop scratching and return to living more productive lives. Obviously, we’ll need to do a larger study, but the early results are very encouraging.”
The findings also explain why an earlier study found that itching dissipates dramatically in eczema patients treated with the new drug dupilumab (Dupixent). Eczema patients have itchy, scaly rashes. The Washington University researchers found that drugs such as tofacitinib and dupilumab work so well, where many other drugs have failed, because they act directly on the nerves rather than only on the immune system.
Chronic itch affects up to 15 percent of the population and is most often caused by inflammatory conditions such as eczema and psoriasis but also is associated with kidney failure, liver disease and certain cancers and nerve disorders. However, cases of chronic itching for which there are no known causes are particularly puzzling and among the most difficult to treat.
As part of the study, the researchers showed that sensory neurons in mice and people are activated by the immune signaling molecule called interleukin-4 (IL-4).
“We found a link between the immune system and the nervous system that wasn’t previously appreciated, showing that this immune molecule directly stimulates nerve cells to cause itching,” Kim said.
Further, the researchers showed that IL-4 signaling can jump-start chronic itching in the setting of inflammation but also independently of pathways directly linked to inflammation. Chronic idiopathic pruritus, for example, isn’t associated with inflammation, which is why anti-inflammatory treatments, such as steroid creams, are ineffective.
Kim’s team, led by MD/PhD student and first author Landon K. Oetjen, also engineered mice to have sensory neurons that lacked the ability to respond to IL-4. When these mice were exposed to stimuli that should have made them itch, they didn’t scratch. These findings may help explain why the new drug dupilumab has had such remarkable success in improving itch in patients with eczema.
The researchers then determined that IL-4 stimulates a key protein within nerve cells – JAK1 – that is a critical component of chronic itching. That finding led the team to suspect that JAK1 may be a uniquely sensitive target for multiple types of itch, even itching of unknown cause. The existing arthritis drug tofacitinib blocks this protein, so several of Kim’s patients with chronic idiopathic pruritus were given the drug.
“We didn’t know if tofacitinib would work in patients with chronic idiopathic pruritus, but our studies in mice suggested it might,” Kim said.
Although the patients with chronic idiopathic pruritus usually didn’t have rashes on their skin, they still had severe and debilitating itch. But when taking tofacitinib, those patients experienced, on average, almost an 80 percent improvement in their itch severity.
“It’s a rare situation where our mouse studies precisely predict what we’re seeing in human patients,” Kim said. “Next, we want to carry out larger studies in patients with chronic itch to evaluate whether tofacitinib can be modified to eliminate itching without also interfering with the patients’ immune systems.”
Oetjen LK, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell, Sept. 7, 2017.
This work was supported by the National Center for Advancing Translational Sciences; the National Cancer Institute; the National Center for Research Resources; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute of Allergy and Infectious Diseases; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; and the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH), grant numbers UL1 TR000448, P30 CA91842, 1S10 RR027552, P30 DK052574, U19 AI070489, R01 NS042595, R21 AR068012, R01 DK097, U01 AI95550, R01 AI077600, K08 AR065577, R01 AR070116, T23 HL007317. Additional funding was provided by the American Skin Association, the Doris Duke Charitable Foundation and a research grant from LEO Pharma.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.